All In Biotech

Drug Trial Radar · NCT04737213

SGM-101 in Colorectal Lung Metastases

An Open-label, Exploratory Study Assessing the Feasibility of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Lung Metastasis in Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Feb 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

10

Planned (sponsor's estimate)

Start

Nov 1, 2020

Primary completion

Nov 1, 2021

Study completion Dec 1, 2021

Sponsor

Lead sponsor
Leiden University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Erasmus Medical Center; Surgimab
First posted
Feb 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Near-infrared fluorescence-guided oncologic surgery (FGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness. SGM-101 already proven to be safe and valuable in colorectal cancer. This study aims to prove feasibility for colorectal lung metastases.

Conditions

  • Colorectal Cancer
  • Metastatic Colon Cancer

Interventions

  • SGM-101Drug

    Fluorescence guided surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.Time frame: peroperative

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Erasmus Medical Center

    Rotterdam, Netherlands · Not yet recruiting

  • Leiden University Medical Center

    Leiden, South Holland, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.